Senzime
Uppsala
About Senzime
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $5.9M
- Funding stage: IPO
- Last round: Post-IPO Debt (Feb 2026)
- Ticker: otcpink:SNZZF
- Website: senzime.com
- Phone: +46 (0)18-51 56 40
Industries & Categories
Health Diagnostics, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/senzime-99910 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.